We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi's (SNY) Meningitis Vaccine MenQuadfi Wins EU Approval
Read MoreHide Full Article
Sanofi (SNY - Free Report) announced that the European Commission (EC) has approved its fully-liquid meningococcal vaccine MenQuadfi for the active immunization of individuals, aged 12 months and above against meningococcal meningitis, which is a rare and deadly bacterial infection.
The nod in Europe was based on data from seven pivotal phase II and III studies, which evaluated the immunogenicity and safety of MenQuadfi in more than 6,300 healthy individuals. Data from the same showed that treatment with MenQuadfi demonstrated a good safety profile and led to a high immune response against four of the major meningococcal disease serogroups (A, C, Y, W) in patients, aged 12 months and above.
Per the company, more than 3,000 cases of meningococcal disease are reported in Europe every year. Following this nod, MenQuadfi becomes the first fully-liquid quadrivalent meningococcal conjugate vaccine in Europe.
Notably, in April 2020, MenQuadfi was approved in the United States for the prevention of meningococcal meningitis in patients, aged two years and above.
We note that additional phase III studies on MenQuadfi are currently ongoing for the prevention of meningococcal disease in infants from six weeks of age.
Shares of Sanofi have lost 0.7% so far this year compared with the industry’s decrease of 0.2%.
We remind investors that Sanofi possesses one of the world’s leading vaccine operations. Apart from the meningitis vaccine, the company’s portfolio includes pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines plus travel and endemic vaccines. Sanofi also holds a strong position in both seasonal and pre-pandemic influenza vaccine spaces. The company is actively engaged in developing a vaccine for the deadly COVID-19 disease.
Sanofi along with GlaxoSmithKline (GSK - Free Report) is developing an adjuvanted COVID-19 vaccine in a phase I/II clinical study. Data from the same is expected in December. The companies plan to produce 1 billion doses of the adjuvant vaccine in 2021.
Meanwhile, Sanofi and Translate Bio, Inc. (TBIO - Free Report) are jointly developing a novel messenger RNA (mRNA) vaccine candidate MRT5500 for COVID-19. The candidate demonstrated a favorable immune response against SARS-CoV-2 in pre-clinical studies. A phase I/II study on MRT5500 is expected to begin in the fourth quarter of 2020.
We note that currently, Pfizer/BioNTech’s mRNA-based coronavirus vaccine candidate BNT162b2 proved to be 95% effective in its final analysis. Meanwhile, Moderna’s (MRNA - Free Report) mRNA-based coronavirus vaccine candidate mRNA-1273 demonstrated a vaccine efficacy of 94.5% in the first interim analysis.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Sanofi's (SNY) Meningitis Vaccine MenQuadfi Wins EU Approval
Sanofi (SNY - Free Report) announced that the European Commission (EC) has approved its fully-liquid meningococcal vaccine MenQuadfi for the active immunization of individuals, aged 12 months and above against meningococcal meningitis, which is a rare and deadly bacterial infection.
The nod in Europe was based on data from seven pivotal phase II and III studies, which evaluated the immunogenicity and safety of MenQuadfi in more than 6,300 healthy individuals. Data from the same showed that treatment with MenQuadfi demonstrated a good safety profile and led to a high immune response against four of the major meningococcal disease serogroups (A, C, Y, W) in patients, aged 12 months and above.
Per the company, more than 3,000 cases of meningococcal disease are reported in Europe every year. Following this nod, MenQuadfi becomes the first fully-liquid quadrivalent meningococcal conjugate vaccine in Europe.
Notably, in April 2020, MenQuadfi was approved in the United States for the prevention of meningococcal meningitis in patients, aged two years and above.
We note that additional phase III studies on MenQuadfi are currently ongoing for the prevention of meningococcal disease in infants from six weeks of age.
Shares of Sanofi have lost 0.7% so far this year compared with the industry’s decrease of 0.2%.
We remind investors that Sanofi possesses one of the world’s leading vaccine operations. Apart from the meningitis vaccine, the company’s portfolio includes pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines plus travel and endemic vaccines. Sanofi also holds a strong position in both seasonal and pre-pandemic influenza vaccine spaces. The company is actively engaged in developing a vaccine for the deadly COVID-19 disease.
Sanofi along with GlaxoSmithKline (GSK - Free Report) is developing an adjuvanted COVID-19 vaccine in a phase I/II clinical study. Data from the same is expected in December. The companies plan to produce 1 billion doses of the adjuvant vaccine in 2021.
Meanwhile, Sanofi and Translate Bio, Inc. (TBIO - Free Report) are jointly developing a novel messenger RNA (mRNA) vaccine candidate MRT5500 for COVID-19. The candidate demonstrated a favorable immune response against SARS-CoV-2 in pre-clinical studies. A phase I/II study on MRT5500 is expected to begin in the fourth quarter of 2020.
We note that currently, Pfizer/BioNTech’s mRNA-based coronavirus vaccine candidate BNT162b2 proved to be 95% effective in its final analysis. Meanwhile, Moderna’s (MRNA - Free Report) mRNA-based coronavirus vaccine candidate mRNA-1273 demonstrated a vaccine efficacy of 94.5% in the first interim analysis.
Zacks Rank
Sanofi currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>